Key Takeaways
- U.S. Central Command (CENTCOM) confirms striking approximately 80-90 Iranian military targets following reports of explosions in coastal cities, including Konarak and Bushehr, home to Iran's nuclear power plant.
- AstraZeneca (AZN) wins a major patent appeal as a U.S. court upholds the invalidation of two Pfizer (PFE) patents, protecting billions in revenue for the lung cancer treatment Tagrisso.
- Elon Musk (TSLA) acknowledges Anthropic as the "clear leader" in AI, praising its Mythos/Fable models and pledging not to restrict the company's access to critical infrastructure.
- ECB President Christine Lagarde calls for European tech sovereignty, urging the continent to "invent" and "bind" its own critical tech tools to secure global supply chain leverage.
- Lagarde hints at a potential early exit from the ECB to participate in the upcoming French presidential election, stressing that a "European voice" must be heard in the domestic debate.
Middle East Conflict Escalates with U.S. Strikes on Iranian Ports
The geopolitical landscape shifted sharply on Thursday as U.S. Central Command (CENTCOM) launched a second night of airstrikes against Iranian military infrastructure. Reports from the Iranian news agency Mehr and state media IRNA confirmed multiple explosions in the port cities of Konarak, Chabahar, and Bandar Abbas. The strikes targeted Islamic Revolutionary Guard Corps (IRGC) assets, including small boats and anti-ship missile sites, in response to recent attacks on commercial vessels in the Strait of Hormuz.
The escalation has put the region on high alert, with sirens reported in Bahrain and retaliatory fire from Tehran directed at Kuwait and Qatar. Iranian officials accused the U.S. of "gross war crimes" and "MoU violations," threatening the stability of a fragile ceasefire established in June. Markets are closely monitoring the situation as Bushehr, the site of Iran's only commercial nuclear power plant, was among the locations where blasts were heard.
Pfizer Loses Legal Battle Over Blockbuster Cancer Drug Patents
In a significant blow to its oncology portfolio, Pfizer (PFE) failed to overturn a court decision that cancelled patents related to the lung cancer drug Tagrisso. The U.S. Court of Appeals for the Federal Circuit upheld a lower court ruling that the patents, originally held by Pfizer subsidiary Wyeth, were invalid due to a lack of sufficient written descriptions. This decision cements a victory for AstraZeneca (AZN), which saw Tagrisso generate over $7.2 billion in global revenue last year.
The legal defeat means Pfizer will not be able to collect on a previous $107.5 million jury award. This setback comes at a critical time for Pfizer, as the company faces a "patent cliff" with several top-selling drugs, including Eliquis and Ibrance, set to lose protection in the coming years. Investors remain focused on Pfizer's ability to replace this lost revenue through its $43 billion acquisition of Seagen and other pipeline developments.
Elon Musk Pivots on AI Competition, Praises Anthropic
Billionaire Elon Musk (TSLA) made waves in the tech industry by admitting he was "wrong" about Anthropic, now calling the startup the "clear leader in AI." Musk noted that no current competitor matches the capabilities of Anthropic’s Mythos and Fable models, with Mythos 2 expected to launch imminently. In a surprising show of competitive philosophy, Musk pledged that he would never cut off Anthropic in a way that would harm the company, comparing his stance to Tesla's decision to open-source its patents.
This endorsement coincides with the public release of OpenAI's GPT-5.6 Sol, intensifying the "frontier model" race. While the U.S. government recently lifted export controls on Anthropic's Fable model, the more advanced Mythos remains restricted to "trusted" organizations due to its potential for identifying cybersecurity vulnerabilities. Musk's comments suggest a shifting alliance in the AI sector as companies navigate both rapid innovation and tightening national security regulations.
Lagarde Pushes for Tech Independence Amid Political Ambitions
European Central Bank (ECB) President Christine Lagarde used a high-level forum to advocate for a more assertive European technology policy. Speaking on #TheEuropeConversation, Lagarde argued that critical tech tools must be "invented in Europe" to prevent over-reliance on foreign entities. She called for a strategic "linking and binding" of European tech components to gain leverage in global supply chain negotiations, particularly as AI and semiconductors become central to economic security.
Beyond economic policy, Lagarde addressed the upcoming French presidential election, expressing hope that "reason will always prevail." She indicated that an early departure from her role at the ECB is "possible" to ensure a "European voice" is represented in the French political debate. With her term currently set to end in October 2027, any early exit would introduce significant leadership uncertainty for the central bank during a period of persistent inflation and geopolitical volatility.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.